The GNAQ Knockout HEK293T Polyclonal Cells constitute a human embryonic kidney HEK293T-based polyclonal population with targeted disruption of the GNAQ gene via CRISPR/Cas9-mediated gene editing. This knockout model provides a heterogeneous pool of cells carrying diverse loss-of-function mutations in GNAQ, enabling robust and reproducible analysis of G??q-dependent signaling without the clonal selection bias inherent in monoclonal cell lines. The polyclonal format is particularly suited for applications requiring representative population-level responses, such as pharmacological profiling and pathway dissection in a physiologically relevant cellular context. By abrogating G??q protein expression, these cells serve as a critical tool for elucidating Gq-coupled GPCR signaling networks and validating target engagement in drug discovery pipelines.
HEK293T cells are a widely utilized derivative of the HEK293 line, immortalized by adenovirus 5 DNA and engineered to stably express the SV40 large T-antigen. This antigen facilitates episomal replication of plasmids containing the SV40 origin of replication, dramatically enhancing transient protein expression and viral vector production. Their epithelial origin, high transfectability, and robust growth characteristics have established HEK293T as a versatile workhorse for heterologous expression studies, lentiviral packaging, and biochemical characterization of recombinantly introduced signaling components. The endogenous complement of many signaling effectors??including G proteins, phospholipase C isoforms, and downstream kinases??makes HEK293T an ideal background for interrogating G??q-mediated pathways when combined with targeted gene knockout.
The GNAQ gene encodes G??q, the effector-activating ??-subunit of heterotrimeric Gq proteins. Upon ligation of cognate G-protein-coupled receptors such as the 5-HT2A serotonin receptor or AT1 angiotensin II receptor, G??q exchanges GDP for GTP, dissociates from G?¦? dimers, and directly stimulates phospholipase C ?? (PLC??1-4). Activated PLC?? hydrolyzes phosphatidylinositol 4,5-bisphosphate to generate the second messengers inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers release of intracellular Ca2+ from endoplasmic reticulum stores, leading to calmodulin-dependent kinase activation and calcineurin-mediated dephosphorylation of nuclear factor of activated T-cells (NFAT). Concurrently, DAG activates protein kinase C (PKC) isoforms, which engage downstream MAP kinase cascades??including ERK1/2 and JNK??and, via Rho guanine nucleotide exchange factors such as p63RhoGEF, stimulate RhoA-driven cytoskeletal reorganization. RGS proteins (e.g., RGS2, RGS4, RGS16) accelerate GTP hydrolysis to terminate signaling, while GRK2/3 and TRPC channels further modulate G??q output.
In the HEK293T context, disruption of GNAQ creates a clean loss-of-function system to dissect the specific contribution of G??q to cellular signaling without confounding endogenous expression. This model is especially valuable for studying oncogenic pathways, as activating mutations in GNAQ are drivers in uveal melanoma and other melanocytic neoplasms. Knockout cells allow researchers to compare wild-type versus G??q-null backgrounds for Gq-dependent phenotypic readouts, including cell proliferation, calcium mobilization, and gene expression changes. The polyclonal nature ensures that observed effects are not artifacts of single-clone adaptation, thereby strengthening statistical conclusions in pooled CRISPR screening and drug sensitivity assays. It also facilitates the study of adaptive resistance mechanisms that may arise when G??q signaling is abrogated.
These polyclonal knockout cells are suited for a broad range of investigative applications, including GPCR signaling studies, calcium flux analyses using fluorescent indicators (Fluo-4, Fura-2), phospho-ERK1/2 immunoblotting, and NFAT-responsive luciferase reporter assays. They enable rigorous validation of G??q-specific antibodies by providing a true negative control and can be employed in co-immunoprecipitation experiments to map receptor?CG protein interactions. Drug target validation in uveal melanoma research and screening for inhibitors of Gq-dependent oncogenic pathways are further key uses. For further information or to request a quote, please contact Ascent Research.
